spacer
home > pmps > autumn 2008 > the future’s bright
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future’s Bright

How do you think your sector has developed over the past 10 years?

Temperature controlled packaging has become a defined sector in the last 10 years, driven by the increasing use of biological products in the healthcare sector, such as erythropoietins for the treatment of anaemia and beta interferons for multiple sclerosis, anti-inflammatories and cancer treatments. These largely protein-based products are highly sensitive to temperature, requiring careful storage and distribution in order to be effective. The range from +2 to +8°C is such a prevalent specification that it has become a de facto standard. Other temperature requirements have since emerged, most notably temperate (+15 to +25 or +30°C). Regulatory awareness, notably that of the US FDA and the UK’s MHRA, and industry practice in the form of GxPs have kept pace with these demands, as has an array of shipping technologies, both passive and active.

What would you perceive as the biggest challenges facing the industry over the next 10 years?

The challenge now is to harmonise standards across an increasingly global platform. Industrial and international cooperation...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tim Jennings is a Director of the French company Emball’iso SA and of two of its international affiliates. He has 10 years’ experience in the shipping of temperature sensitive products at two of the leading European companies in the field. Prior to these commercial roles Tim worked in the supply of engineering design and consultancy services to the pharmaceutical and petrochemical industries, specialising in ion exchange and adsorbent processes. Tim has a BSc (Hons) in Materials Technology.
spacer
Tim Jennings
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

[Noáin, April 22, 2020] 3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement